M&A
Subrata Roy’s Plaza Hotel to be auctioned for mortgage defaults
By By Ravi Kunder | 17 Mar 2016
The five-star hotel off Central Park is majority owned by Subrata Roy’s Sahara India Pariwar, which defaulted on the mortgage payments By Ravi Kunder
China's Zoomlion sweetens bid for US crane maker Terex Corp to $3.4 bn
16 Mar 2016
Zoomlion believes the deal offers strategic benefits to both companies since Terex's main products are aerial work platforms, cranes and material handling equipment
Sony to buy Michael Jackson’s stake in Sony ATV JV for $750 mn
15 Mar 2016
ATV was founded in 1955 and acquired by Michael Jackson in 1985 for $41.5 million. In 1995, Michael Jackson merged his share with Sony's music-publishing catalogue to form Sony ATV
China's Anbang launches hostile $12.84-bn bid for Starwood Hotels
14 Mar 2016
A consortium led by China's Anbang Insurance Group has launched an unsolicited $12.84-billion bid to acquire Starwood Hotels and Resorts, potentially derailing the already planned takeover of the US hotel operator by Marriott International
Waldorf's Chinese owner Anbang to buy Strategic Hotels for $6.5 bn
14 Mar 2016
The Beijing-based insurer has recently made a push into buying overseas assets and made some high profile acquisitions
GM to buy autonomous vehicle technology software start-up Cruise Automation
12 Mar 2016
GM recently started dabbling in self-driving vehicle technology, and invested $500 million in Lyft, Inc an automated on-demand rides company, which led to starting its own car-sharing service company called Maven
European regulator approves Teva’s $40.5-bn Allergan drug unit deal with conditions
11 Mar 2016
The European Commission yesterday approved Teva Pharmaceutical Industries' $40.5-billion acquisition of the generics drug unit of Allergan on condition that it divests some Allergan products in the UK and Ireland
European regulator approves Teva’s $40.5-bn Allergan drug unit deal with conditions
11 Mar 2016
The European Commission yesterday approved Teva Pharmaceutical Industries' $40.5-billion acquisition of the generics drug unit of Allergan on condition that it divests some Allergan products in the UK and Ireland
European regulator approves Teva’s $40.5-bn Allergan drug unit deal with conditions
11 Mar 2016
The European Commission yesterday approved Teva Pharmaceutical Industries' $40.5-billion acquisition of the generics drug unit of Allergan on condition that it divests some Allergan products in the UK and Ireland